Abstract
After decades of slow progress in the management of follicular lymphoma (FL), important strides are occurring. An aim for cure is realistic and appropriate for some patients, including those with stage I–II disease, some histologic subtypes of FL (e.g., FL grade 3b) and even some relapsing patients following allogeneic stem cell transplantation approaches. Survival outcomes are improving, probably in large part related to the inclusion of anti-CD20 monoclonal antibodies in current treatment strategies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
